Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 1/20 | 0.45 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 2/20 | 0.43 |
| ▸ | CNR2 | P34972 | 2/20 | 0.43 |
| ▸ | HPGDS | O60760 | 8/20 | 0.40 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29779623 | 0.91 | HDAC3 (0.41) | HPGDSHDAC3HDAC2PDPK1MCHR1 | |
| SCHEMBL23167369 | 0.91 | HDAC3 (0.41) | HPGDSHDAC3HDAC2PDPK1MCHR1 | |
| SCHEMBL25138359 | 0.87 | HPGDS (0.42) | HPGDSMCHR1 | |
| SCHEMBL23167363 | 0.84 | FGFR1 (0.48) | FGFR1FGFR4HDAC3HDAC2 | |
| SCHEMBL23167492 | 0.82 | FGFR1 (0.48) | FGFR1FGFR4HDAC3HDAC2 | |
| SCHEMBL23201985 | 0.72 | SLC22A12 (0.44) | HDAC3HDAC2 | |
| SCHEMBL24626551 | 0.68 | SMYD3 (0.48) | CNR1CNR2SMYD3 | |
| SCHEMBL29675197 | 0.68 | SMYD3 (0.48) | CNR1CNR2SMYD3 | |
| SCHEMBL16794776 | 0.67 | FGFR1 (0.56) | FGFR1FGFR4HDAC3HDAC2 | |
| SCHEMBL16794758 | 0.64 | FGFR1 (0.55) | FGFR1FGFR4HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230123856-A1 | 5-FLUORONICOTINAMIDE DERIVATIVES AND USES THEREOF | TENAYA THERAPEUTICS, INC. (US) | 2023-04-20 | — | — | US | disclosed |
| EP-4037670-A1 | 5-FLUORONICOTINAMIDE DERIVATIVES AND USES THEREOF | Tenaya Therapeutics, Inc. (US) | 2022-08-10 | — | — | EP | disclosed |
| WO-2021067859-A1 | 5-FLUORONICOTINAMIDE DERIVATIVES AND USES THEREOF | TENAYA THERAPEUTICS, INC. (US) | 2021-04-08 | — | — | WO | disclosed |
| WO-2021067859-A1 | 5-FLUORONICOTINAMIDE DERIVATIVES AND USES THEREOF | TENAYA THERAPEUTICS, INC. (US) | 2021-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230123856-A1 | 5-FLUORONICOTINAMIDE DERIVATIVES AND USES THEREOF | SLC28A1, SLC5A1, SLC9A5 | FGFR1 26/4885FGFR4 194/4885CNR1 3061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.